Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$47.99

-0.7 (-1.44%)

08:55
01/09/18
01/09
08:55
01/09/18
08:55

Portola Pharmaceuticals to host a webcast

Management holds an investor update on the Company's commercial launch for Bevyxxa (Betrixaban) on a webcast on January 9 at 10 am. Webcast Link

  • 09

    Jan

  • 02

    Feb

  • 04

    May

PTLA Portola Pharmaceuticals
$47.99

-0.7 (-1.44%)

12/01/17
12/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hormel Foods (HRL) reinstated with an Overweight at Barclays. 2. Kratos Defense (KTOS) initiated with a Neutral at JPMorgan. 3. Portola Pharmaceuticals (PTLA) initiated with a Buy at Goldman Sachs. 4. Diamondback Energy (FANG) initiated with a Buy at Citi. 5. Booz Allen (BAH) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/26/17
WBLR
12/26/17
NO CHANGE
WBLR
Outperform
William Blair still sees FDA approval for Portola's AndexXa
William Blair analyst Matt Phipps says that while the FDA extension is "undoubtedly a disappointment to investors," he continues to believe Portola Pharmaceuticals' AndexXa will receive approval. The request for information from the FDA only pertained to information from the ANNEXA-4 study, and did not include additional questions regarding the manufacturing of AndexXa, which was the primary reason for the original complete response letter, Phipps tells investors in a research note. The analyst sees AndexXa gaining approval in the United States and Europe in the near term. This, combined with the commercial launch of Bevyxxa, provides "significant upside potential" to current share prices, Phipps contends. He keeps an Outperform rating on Portola. The stock closed Friday down 6% to $51.80.
12/28/17
SBSH
12/28/17
NO CHANGE
Target $78
SBSH
Buy
Citi still expects FDA approval for Portola despite 90 day delay
After speaking to management, Citi analyst Yigal Nochomovitz expects Portola Pharmaceuticals' AndexXa to be approved on or before the new FDA action date of May 4, 2018. The additional data, which led to the 90 day delay, pertain, at least in part, to an update on thrombotic events in ANNEXA-4 since the last cut, Nochomovitz tells investors in a research note. The analyst believes the FDA may be using the new data submitted to refine label language on when to recommend restarting anti-coagulation. He says he would be "very surprised" if the FDA cannot reach a positive decision without a panel hearing. Nochomovitz keeps a Buy rating on Portola with a $74 price target. The stock closed yesterday down 2% to $47.82.
12/29/17
OPCO
12/29/17
NO CHANGE
Target $80
OPCO
Outperform
Portola 14% selloff brings buying opportunity, says Oppenheimer
Oppenheimer analyst Jay Olson believes the 14% pullback in Portola Pharmaceuticals since the company disclosed on December 22 a three-month delay to the AndexXa FDA action date presents a buying opportunity. The decline is unwarranted as Portola plans to launch two new drugs in 2018, each with sales potential exceeding $1B at peak, Olson tells investors in a research note titled "Stop the Bleeding! Overreaction to AndexXa Delay Creates Buying Opportunity." The analyst sees the three-month delay to AndexXa as "essentially immaterial" to his outlook for the company. Olson reiterates an Outperform rating on Portola Pharmaceuticals with an $80 price target. The stock closed yesterday down 57c to $47.25.

TODAY'S FREE FLY STORIES

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:55
08/14/18
08/14
16:55
08/14/18
16:55
Hot Stocks
LRAD Corporation says 'well positioned to achieve record fiscal year revenues' »

"LRAD is in a much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:54
08/14/18
08/14
16:54
08/14/18
16:54
Hot Stocks
Breaking Hot Stocks news story on LRAD Corporation »

LRAD Corporation reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:53
08/14/18
08/14
16:53
08/14/18
16:53
Earnings
LRAD Corporation reports Q3 EPS 0c, one estimate 0c »

Reports Q3 revenue $7.5M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

CDNA

CareDx

$16.87

-0.13 (-0.76%)

16:50
08/14/18
08/14
16:50
08/14/18
16:50
Hot Stocks
CareDx CFO Michael Brian Bell sells 12,500 shares of company stock »

CareDx CFO Michael Brian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

VNDA

Vanda Pharmaceuticals

$21.60

0.15 (0.70%)

16:46
08/14/18
08/14
16:46
08/14/18
16:46
Hot Stocks
Vanda Pharmaceuticals wins denial of petition for rehearing on Fanapt »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$193.08

-1.03 (-0.53%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Recommendations
Home Depot analyst commentary  »

Home Depot underlying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Diamondback Energy »

Diamondback Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$98.41

1.32 (1.36%)

, UTX

United Technologies

$132.40

0.23 (0.17%)

16:42
08/14/18
08/14
16:42
08/14/18
16:42
Hot Stocks
Pershing Square adds Lowe's, cuts stake in ADP »

Bill Ackman's…

LOW

Lowe's

$98.41

1.32 (1.36%)

UTX

United Technologies

$132.40

0.23 (0.17%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

ADP

ADP

$141.17

1.48 (1.06%)

QSR

Restaurant Brands

$62.20

0.355 (0.57%)

CMG

Chipotle

$493.33

8.97 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 22

    Aug

  • 07

    Sep

  • 11

    Sep

  • 12

    Sep

  • 24

    Sep

DXC

DXC Technology

$86.56

2.02 (2.39%)

16:41
08/14/18
08/14
16:41
08/14/18
16:41
Hot Stocks
DXC Technology awarded $400M contract by Wisconsin DHS »

The Wisconsin Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

16:39
08/14/18
08/14
16:39
08/14/18
16:39
General news
API crude inventories for week of August 10 »

API reports that crude…

CSOD

Cornerstone OnDemand

$52.59

0.48 (0.92%)

16:35
08/14/18
08/14
16:35
08/14/18
16:35
Recommendations
Cornerstone OnDemand analyst commentary  »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 04

    Sep

  • 06

    Sep

  • 07

    Sep

  • 12

    Sep

  • 12

    Sep

ATNM

Actinium Pharmaceuticals

$0.62

0.003 (0.49%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Conference/Events
Actinium Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Earnings
Perspecta sees FY18 pro forma revenue $4.150B-$4.250B, consensus $4.2B »

Sees FY19 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FCN

FTI Consulting

$80.32

0.33 (0.41%)

16:33
08/14/18
08/14
16:33
08/14/18
16:33
Syndicate
Breaking Syndicate news story on FTI Consulting »

FTI Consulting files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:32
08/14/18
08/14
16:32
08/14/18
16:32
Hot Stocks
Perspecta reports Q1 adjusted EPS 54c, consensus 46c »

Reports Q1 revenue $793M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SBBP

Strongbridge Biopharma

$6.25

0.3 (5.04%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Syndicate
Strongbridge Biopharma files to sell 9M ordinary shares »

Cowen and Stifel are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HWC

Hancock Whitney

$51.40

0.6 (1.18%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Hancock Whitney names Christopher Ziluca as new Chief Credit Officer »

Hancock Whitney has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRI

Atrion

$656.00

9 (1.39%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Atrion increases quarterly cash dividend by 13% »

Atrion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIK

Tel-Instrument

$2.60

(0.00%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Tel-Instrument receives NYSE non-compliance letter »

Tel Instrument…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/14/18
08/14
16:30
08/14/18
16:30
Options
Preliminary option volume of 16.1M today »

Preliminary option volume…

DLPN

Dolphin Entertainment

$2.96

(0.00%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Earnings
Dolphin Entertainment reports Q2 EPS (1c), consensus 2c »

Reports Q2 revenue $5.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

BK

BNY Mellon

$50.97

0.825 (1.65%)

, GE

General Electric

$12.35

-0.09 (-0.72%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Hot Stocks
Trian Fund boosts BNY Mellon, lowers stake in Wendy's »

Nelson Peltz's Trian…

BK

BNY Mellon

$50.97

0.825 (1.65%)

GE

General Electric

$12.35

-0.09 (-0.72%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

WEN

Wendy's

$17.84

0.48 (2.77%)

SYY

Sysco

$74.19

1.47 (2.02%)

PG

Procter & Gamble

$81.31

-0.21 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 07

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

16:28
08/14/18
08/14
16:28
08/14/18
16:28
Syndicate
ViewRay files to sell $125M of common stock »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

LMB

Limbach Holding

$10.70

0.11 (1.04%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Limbach Holding raises FY18 revenue view to $530-$550M from $520M-$540M »

Consensus $527.77M. Now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

MRSN

Mersana Therapeutics

$12.75

0.04 (0.31%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Mersana Therapeutics reports Q2 EPS (54c), consensus (58c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 15

    Aug

  • 04

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.